| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BBALIP.2011.10.016 |
| P698 | PubMed publication ID | 22056763 |
| P50 | author | Bart Staels | Q28360345 |
| Kristiaan Wouters | Q56508039 | ||
| Anne Tailleux | Q56898783 | ||
| P2860 | cites work | Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice | Q30513404 |
| Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice | Q36130584 | ||
| Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates | Q38316076 | ||
| Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice | Q43180173 | ||
| Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis | Q46455735 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 809-818 | |
| P577 | publication date | 2011-10-25 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Roles of PPARs in NAFLD: potential therapeutic targets | |
| P478 | volume | 1821 |
| Q90442272 | A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors |
| Q47200557 | Ablating both Fabp1 and Scp2/Scpx (TKO) Induces Hepatic Phospholipid and Cholesterol Accumulation in High Fat-fed Mice |
| Q89380654 | Agaricus brasiliensis (sun mushroom) affects the expression of genes related to cholesterol homeostasis |
| Q36911049 | Alternating Diet as a Preventive and Therapeutic Intervention for High Fat Diet-induced Metabolic Disorder |
| Q42701165 | Amelioration of free fatty acid-induced fatty liver by quercetin-3-O-β-D-glucuronide through modulation of peroxisome proliferator-activated receptor-alpha/sterol regulatory element-binding protein-1c signaling |
| Q112648225 | CD11c-MHC2low Macrophages Are a New Inflammatory and Dynamic Subset in Murine Adipose Tissue |
| Q28550623 | Chemical and Hormonal Effects on STAT5b-Dependent Sexual Dimorphism of the Liver Transcriptome |
| Q35586085 | Choline and Fructooligosaccharide: Non-alcoholic Fatty Liver Disease, Cardiac Fat Deposition, and Oxidative Stress Markers |
| Q47718804 | Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice |
| Q37673273 | Cinnamic Acid and Its Derivatives: Mechanisms for Prevention and Management of Diabetes and Its Complications |
| Q40958800 | Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease |
| Q38845683 | Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver Disease |
| Q38718576 | Creatine supplementation as a possible new therapeutic approach for fatty liver disease: early findings. |
| Q37196514 | Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease |
| Q37554361 | Cytochrome P450-2E1 promotes fast food-mediated hepatic fibrosis |
| Q64071585 | Dietary Polyphenols Protect Against Oleic Acid-Induced Steatosis in an in Vitro Model of NAFLD by Modulating Lipid Metabolism and Improving Mitochondrial Function |
| Q44206097 | Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor δ activation |
| Q64921712 | Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. |
| Q37706430 | Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice |
| Q42292936 | Eggshell membrane ameliorates hepatic fibrogenesis in human C3A cells and rats through changes in PPARγ-Endothelin 1 signaling |
| Q38293506 | Emerging small molecule drugs |
| Q92246424 | Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis |
| Q39017725 | Evodiamine might inhibit TGF-beta1-induced epithelial-mesenchymal transition in NRK52E cells via Smad and PPAR-gamma pathway |
| Q33613330 | Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias |
| Q39903509 | Fatty Liver, Insulin Resistance, and Obesity: Relationships With Increase in Coronary Artery Calcium Over Time |
| Q84915248 | Fatty liver and anti-oxidant enzyme activities along with peroxisome proliferator-activated receptors γ and α expressions in the liver of Wilson's disease |
| Q36334667 | Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people |
| Q47970720 | Ferulic acid improves lipid and glucose homeostasis in high-fat diet-induced obese mice |
| Q38766181 | Free Fatty Acids Increase Intracellular Lipid Accumulation and Oxidative Stress by Modulating PPARα and SREBP-1c in L-02 Cells |
| Q34041838 | GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes |
| Q36423203 | Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. |
| Q92889825 | Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study |
| Q34036872 | Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis |
| Q43529289 | Hibiscus sabdariffa L. aqueous extract attenuates hepatic steatosis through down-regulation of PPAR-γ and SREBP-1c in diet-induced obese mice |
| Q37062345 | High glucose potentiates L-FABP mediated fibrate induction of PPARα in mouse hepatocytes |
| Q51243542 | High-Fructose Intake Impairs the Hepatic Hypolipidemic Effects of a High-Fat Fish-Oil Diet in C57BL/6 Mice. |
| Q50226445 | Hovenia Dulcis Extract Reduces Lipid Accumulation in Oleic Acid-Induced Steatosis of Hep G2 Cells via Activation of AMPK and PPARα/CPT-1 Pathway and in Acute Hyperlipidemia Mouse Model |
| Q33913300 | Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-α activation in cultured human female hepatocytes |
| Q45061974 | Human germline hedgehog pathway mutations predispose to fatty liver. |
| Q53688960 | Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. |
| Q30251565 | Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease |
| Q28543435 | Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium |
| Q48215406 | Inflammation is independent of steatosis in a murine model of steatohepatitis |
| Q28539042 | Inhibitory effects of Japanese herbal medicines sho-saiko-to and juzen-taiho-to on nonalcoholic steatohepatitis in mice |
| Q64355676 | Insights into the Role of PPARβ/δ in NAFLD |
| Q90265159 | Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Non-alcoholic Fatty Liver Disease |
| Q24564130 | Integrated physiology and systems biology of PPARα |
| Q91831828 | LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease |
| Q35911451 | Loss of L-FABP, SCP-2/SCP-x, or both induces hepatic lipid accumulation in female mice |
| Q36478196 | Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity |
| Q28539289 | Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices |
| Q34185231 | Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse |
| Q28071265 | Molecular Pathogenesis of NASH |
| Q33890230 | Molecular pathways in non-alcoholic fatty liver disease. |
| Q92026190 | Multi-omics analysis of multiple missions to space reveal a theme of lipid dysregulation in mouse liver |
| Q35983091 | Naturally improving insulin resistance with amorfrutins |
| Q38197690 | Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity. |
| Q60948824 | Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis |
| Q100946503 | Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors |
| Q34730964 | Nuciferine prevents hepatic steatosis and injury induced by a high-fat diet in hamsters |
| Q38768048 | Nuclear receptors and nonalcoholic fatty liver disease |
| Q30402192 | Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. |
| Q91992943 | PPAR δ inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell |
| Q39029023 | PPARs and nonalcoholic fatty liver disease |
| Q36253614 | PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs |
| Q88693222 | PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis |
| Q64094168 | PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation |
| Q37640263 | Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. |
| Q37244257 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation |
| Q46484710 | Perilipin-2 Deletion Impairs Hepatic Lipid Accumulation by Interfering with Sterol Regulatory Element-binding Protein (SREBP) Activation and Altering the Hepatic Lipidome |
| Q48189776 | Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease. |
| Q42245746 | Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease |
| Q38018841 | Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside |
| Q92475652 | Pharmacological Treatment for Non-alcoholic Fatty Liver Disease |
| Q38195808 | Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition |
| Q100514776 | Protective effect of Yi-Qi-Huo-Xue Decoction against ischemic heart disease by regulating cardiac lipid metabolism |
| Q52347014 | Protein-protein interaction analysis of Alzheimer`s disease and NAFLD based on systems biology methods unhide common ancestor pathways. |
| Q57466113 | RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr mice |
| Q38110581 | Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists |
| Q28817618 | Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPARα and L-FABP Expressions in High-Fat-Fed Rats |
| Q36011202 | Structural Correlates of PPAR Agonist Rescue of Experimental Chronic Alcohol-Induced Steatohepatitis |
| Q39285206 | Telmisartan counteracts TGF-β1 induced epithelial-to-mesenchymal transition via PPAR-γ in human proximal tubule epithelial cells |
| Q38016858 | The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury. |
| Q38752520 | The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans |
| Q28552063 | The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice |
| Q51309204 | The anti-obesity and anti-diabetic effects of kaempferol glycosides from unripe soybean leaves in high-fat-diet mice. |
| Q41387586 | The effect of androgen excess on maternal metabolism, placental function and fetal growth in obese dams |
| Q52699074 | The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. |
| Q38432731 | The potential of flavonoids in the treatment of non-alcoholic fatty liver disease |
| Q42372521 | The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction |
| Q38660769 | The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target? |
| Q34401755 | Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats |
| Q54112974 | Ursolic acid in health and disease. |
| Q37716350 | c9,t11-Conjugated linoleic acid ameliorates steatosis by modulating mitochondrial uncoupling and Nrf2 pathway |
| Q33815927 | miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice |
Search more.